Pablo García‐Pavía

2023 ESC Guidelines for the management of cardiomyopathies

Elena Arbelo, Alexandros Protonotarios, Juan R. Gimeno et al. · European Heart Journal · 2023 · 2.4K citations · Full text

Medicine, Cardiology, Internal Medicine +12

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto, Artur Oręziak, Roberto Barriales‐Villa et al. · The Lancet · 2020 · 1.2K citations · Full text

Medicine, Cardiology, Pharmacotherapy +6

Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction

Esther González-López, María Gallego‐Delgado, Gonzalo Guzzo-Merello et al. · European Heart Journal · 2015 · 1.1K citations · Full text

Medicine, Cardiology, Nuclear Medicine +14

Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases

Pablo García‐Pavía, Claudio Rapezzi, Yehuda Adler et al. · European Heart Journal · 2021 · 1.1K citations · Full text

Medicine, Cardiology, Pathology +16

Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies

Martín Ortiz-Genga, Sofía Cuenca, Matteo Dal Ferro et al. · Journal of the American College of Cardiology · 2016 · 473 citations · Full text

Medicine, Cardiology, Genetics +14